The most commonly used biomarkers are PTEN deletion21 and PIK3CA mutation status22, however PTEN mutations are highly common in prostate cancer patients22 and they may not reflect the complex signalling regulation downstream from it23. This evidence concerns the gene PIK3CA and Familial prostate cancer.